Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Marqibo

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Vincristine sulfate liposome injection (VSLI; Marqibo®) is an encapsulated preparation of standard vincristine in sphingomyelin… Expand
2015
2015
Background: Marqibo® (vincristine sulfate LIPOSOME injection, VSLI) is currently approved in the US for treatment of adults with… Expand
2014
2014
BACKGROUND VSLI (Marqibo) is active in advanced non-Hodgkin lymphoma (NHL) and untreated aggressive NHL. Because of its favorable… Expand
  • table 1
  • table 2
  • table 5
  • table 3
  • figure 1
2013
2013
Vincristine sulfate liposome injection (VSLI; Marqibo®; M) is active in relapsed and refractory lymphomas, and approved in the… Expand
2012
2012
The FDA has approved vincristine sulfate liposome injection (Marqibo) to treat adults with Philadelphia chromosome–negative acute… Expand
2011
2011
Marqibo (vincristine sulfate liposome injection, VSLI) is a novel liposomal formulation of vincristine sulfate (VCR) being… Expand
2010
2010
6507 Background: Management of adult ALL patients who relapse is challenging due to highly drug resistant disease and frequent… Expand
Highly Cited
2009
Highly Cited
2009
Marqibo, a sphingosomal/cholesterol encapsulation of vincristine sulfate has targeted, increased, and sustained delivery of… Expand
2009
2009
9067 Background: Preclinical and clinical studies showed that liposomal encapsulation of vincristine sulfate (VCR) results in… Expand
2007
2007
Background: Vincristine sulfate (VCR) is a cell-cycle specific, lipophilic, anti-cancer drug that inhibits cell division by… Expand